Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101
Latest Information Update: 02 Mar 2020
At a glance
- Drugs Agenmestencel-T (Primary) ; Ganciclovir
- Indications Adenocarcinoma; Gastrointestinal cancer
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms TREAT-ME 1
- Sponsors Apceth Biopharma
- 31 May 2019 Status has been changed to completed.
- 31 May 2019 Results assessing safety and tolerabilty of genetically modified autologous mesenchymal stromal cells published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 02 Jun 2015 Tolerability results (phase 1) presented at the 51st Annual Meeting of the American Society of Clinical Oncology. No safety concerns to prevent progression to phase II testing.